ArticleTransfusion2016
Serologic screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay.
Article in Transfusion, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03056378 (Phase I Clinical Trial of Pooled Red Blood Cells for Transfusion), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Clinical Trial of Pooled Red Blood Cells for Transfusion
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Global meta-analysis onPathogens and global health · 2022Pooled it
- Babesiosis and Its Significance in Transfusion Medicine from a European Point of View.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Emerging Tick-borne Infections in the Upper Midwest and Northeast United States Among Patients With Suspected Anaplasmosis.Open forum infectious diseases · 2024Article
- Transfusion-transmittedJournal of clinical microbiology · 2023Review
- Leveraging Donor Populations to Study the Epidemiology and Pathogenesis of Transfusion-Transmitted and Emerging Infectious Diseases.Transfusion medicine reviews · 2023Article
- A Fluorescent Recombinase Aided Amplification Assay for Detection of Babesia microti.The Korean journal of parasitology · 2022Article
- Identification and characterization of extracellular vesicles from red cells infected withFrontiers in cellular and infection microbiology · 2022Article
- Blood identification at the single-cell level based on a combination of laser tweezers Raman spectroscopy and machine learning.Biomedical optics express · 2021Article
- Technologies for Detection ofPathogens (Basel, Switzerland) · 2021Review
- Development of a Multiplex Droplet Digital PCR Assay for the Detection ofPathogens (Basel, Switzerland) · 2021Article
- The Global Emergence of Human Babesiosis.Pathogens (Basel, Switzerland) · 2021Review
- Preventing Transfusion-Transmitted Babesiosis.Pathogens (Basel, Switzerland) · 2021Review
- Review
- Combined Immunofluorescence (IFA) and Fluorescence In Situ Hybridization (FISH) Assays for Diagnosing Babesiosis in Patients from the USA, Europe and Australia.Diagnostics (Basel, Switzerland) · 2020Article
- The Babesia observational antibody (BAOBAB) study: A cross-sectional evaluation of Babesia in two communities in Kilosa district, Tanzania.PLoS neglected tropical diseases · 2019Article
- Persistence ofPathogens (Basel, Switzerland) · 2019Review
- Transfusion-Transmitted Infections Reported to the National Healthcare Safety Network Hemovigilance Module.Transfusion medicine reviews · 2019Article
- BmGPAC, an Antigen Capture Assay for Detection of Active Babesia microti Infection.Journal of clinical microbiology · 2018Article
- Performance Evaluation of a Prototype Architect Antibody Assay for Babesia microti.Journal of clinical microbiology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 10 institutions in 1 country.
Funding
Abstract
backgroundThe tick-borne pathogen Babesia microti has become recognized as the leading infectious risk associated with blood transfusion in the United States, yet no Food and Drug Administration-licensed screening tests are currently available to mitigate this risk. The aim of this study was to evaluate the performance of an investigational enzyme immunoassay (EIA) for B. microti as a screening test applied to endemic and nonendemic blood donor populations. STUDY DESIGN AND
methodsThe study aimed to test 20,000 blood donors from areas of the United States considered endemic for B. microti and 10,000 donors from a nonendemic area with the investigational B. microti EIA. Repeat-reactive samples were retested by polymerase chain reaction (PCR), blood smear, immunofluorescent assay (IFA), and immunoblot assay. In parallel, serum samples from symptomatic patients with confirmed babesiosis were tested by EIA, IFA, and immunoblot assays.
resultsA total of 38 of 13,757 (0.28%) of the donors from New York, 7 of 4583 (0.15%) from Minnesota, and 11 of 8363 (0.13%) from New Mexico were found repeat reactive by EIA. Nine of the 56 EIA repeat-reactive donors (eight from New York and one from Minnesota) were positive by PCR. The specificity of the assay in a nonendemic population was 99.93%. Among IFA-positive clinical babesiosis patients, the sensitivity of the assay was 91.1%.
conclusionThe B. microti EIA detected PCR-positive, potentially infectious blood donors in an endemic population and exhibited high specificity among uninfected and unexposed individuals. The EIA promises to provide an effective tool for blood donor screening for B. microti in a format amenable to high-throughput and cost-effective screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.